Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$2.78 USD
+0.05 (1.83%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $2.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.78 USD
+0.05 (1.83%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $2.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Zacks News
New Strong Buy Stocks for December 5th
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Aimmune Closes Enrolment in Phase III Peanut Allergy Study
by Zacks Equity Research
Aimmune Therapeutics, Inc. (AIMT) announced that it has completed global enrollment in the phase III PALISADE study on AR101
Foamix Completes Enrolment in Phase III Acne Drug Studies
by Zacks Equity Research
Foamix Pharmaceuticals Ltd. (FOMX) announced that it has completed patient enrollment in two phase III studies
Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) announced that it is expanding its sales force to reach primary care physicians.
New Strong Buy Stocks for November 21st
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday